These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 27847554)
21. "NRF2 addiction" in lung cancer cells and its impact on cancer therapy. Hammad A; Namani A; Elshaer M; Wang XJ; Tang X Cancer Lett; 2019 Dec; 467():40-49. PubMed ID: 31574294 [TBL] [Abstract][Full Text] [Related]
22. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592 [TBL] [Abstract][Full Text] [Related]
23. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949 [TBL] [Abstract][Full Text] [Related]
24. Role of the Keap1-Nrf2 pathway in cancer. Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185 [TBL] [Abstract][Full Text] [Related]
25. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771 [TBL] [Abstract][Full Text] [Related]
26. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680 [TBL] [Abstract][Full Text] [Related]
27. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020 [TBL] [Abstract][Full Text] [Related]
28. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506 [TBL] [Abstract][Full Text] [Related]
29. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: Antitumoral effects associated with down-regulation of matrix metalloproteinases. Tertil M; Golda S; Skrzypek K; Florczyk U; Weglarczyk K; Kotlinowski J; Maleszewska M; Czauderna S; Pichon C; Kieda C; Jozkowicz A; Dulak J Free Radic Biol Med; 2015 Dec; 89():147-57. PubMed ID: 26393425 [TBL] [Abstract][Full Text] [Related]
30. Emerging roles of Nrf2 signal in non-small cell lung cancer. Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479 [TBL] [Abstract][Full Text] [Related]
31. Nrf2 protects against airway disorders. Cho HY; Kleeberger SR Toxicol Appl Pharmacol; 2010 Apr; 244(1):43-56. PubMed ID: 19646463 [TBL] [Abstract][Full Text] [Related]
32. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Hu L; Miao W; Loignon M; Kandouz M; Batist G Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992 [TBL] [Abstract][Full Text] [Related]
33. Zinc Finger 521 Modulates the Nrf2-Notch Signaling Pathway in Human Ovarian Carcinoma. Scicchitano S; Faniello MC; Mesuraca M Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834202 [TBL] [Abstract][Full Text] [Related]
34. A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways. Gan FF; Ling H; Ang X; Reddy SA; Lee SS; Yang H; Tan SH; Hayes JD; Chui WK; Chew EH Toxicol Appl Pharmacol; 2013 Nov; 272(3):852-62. PubMed ID: 23899529 [TBL] [Abstract][Full Text] [Related]
35. Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review). Zhu J; Wang H; Fan Y; Lin Y; Zhang L; Ji X; Zhou M Oncol Rep; 2014 Aug; 32(2):443-50. PubMed ID: 24926991 [TBL] [Abstract][Full Text] [Related]
36. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Zhou S; Ye W; Shao Q; Zhang M; Liang J Crit Rev Oncol Hematol; 2013 Dec; 88(3):706-15. PubMed ID: 24126138 [TBL] [Abstract][Full Text] [Related]
37. NRF2 and the Hallmarks of Cancer. Rojo de la Vega M; Chapman E; Zhang DD Cancer Cell; 2018 Jul; 34(1):21-43. PubMed ID: 29731393 [TBL] [Abstract][Full Text] [Related]
38. Keap1-Nrf2 signalling in pancreatic cancer. Hayes AJ; Skouras C; Haugk B; Charnley RM Int J Biochem Cell Biol; 2015 Aug; 65():288-99. PubMed ID: 26117456 [TBL] [Abstract][Full Text] [Related]
39. Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. Müller T; Hengstermann A Chem Res Toxicol; 2012 Sep; 25(9):1805-24. PubMed ID: 22686525 [TBL] [Abstract][Full Text] [Related]
40. Doubling down with inhibitors of Notch and Hedgehog signaling pathways. Weiss GJ J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S409-10. PubMed ID: 23160337 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]